TDMS Study 05024-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus N-METHYLOLACRYLAMIDE DATE: 09/04/94
EXPERIMENT: 05024 TEST: 02 TIME: 04:50:13
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1CP9565302 ROUTE: GAVAGE NTP C#: 60333
PATHOLOGIST: J. TOFT S. EUSTIS CAS: 924-42-5
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus N-METHYLOLACRYLAMIDE DATE: 09/04/94
EXPERIMENT: 05024 TEST: 02 TIME: 04:50:13
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1CP9565302 ROUTE: GAVAGE NTP C#: 60333
PATHOLOGIST: J. TOFT S. EUSTIS CAS: 924-42-5
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus N-METHYLOLACRYLAMIDE DATE: 09/04/94
EXPERIMENT: 05024 TEST: 02 TIME: 04:50:13
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1CP9565302 ROUTE: GAVAGE NTP C#: 60333
PATHOLOGIST: J. TOFT S. EUSTIS CAS: 924-42-5
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF N-METHYLOLACRYLAMIDE
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Harderian Gland Adenoma
Carcinoma or Adenoma
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
All Organs Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Adrenal Medulla Pheochromocytoma Benign
Harderian Gland Adenoma
Carcinoma or Adenoma
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Ovary Granulosa Cell Tumor Benign
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
All Organs Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/48 (4%) 1/20 (5%) 3/50 (6%) | 0/50 (0%) 1/7 (14%) 0/48 (0%) |
|ADJUSTED (b) | 6.4% 0.0% 14.3% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/28 (4%) 0/0 3/21 (14%) | 0/41 (0%) 0/0 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | 683 684 731 (T) | --- 718 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.291 P=0.724 P=0.372 | P=0.706 P=0.469 (e) |
|INCIDENTAL TUMOR | P=0.402 P=0.282 P=0.443 | P=0.620N P=0.128 (e) |
|LOGISTIC REGRESSION | P=0.345 P=0.311 P=0.424 | P=0.676 P=0.008 ** (e) |
|COCHRAN-ARMITAGE | P=0.427 | P=0.692 |
|FISHER EXACT | P=0.655 P=0.520 | P=0.123 (e) |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 14/50 (28%) 29/50 (58%) | 5/50 (10%) 8/50 (16%) 20/49 (41%) |
|ADJUSTED (b) | 3.3% 54.8% 77.6% | 12.2% 22.9% 49.1% |
|TERMINAL (d) | 1/30 (3%) 9/20 (45%) 13/21 (62%) | 5/41 (12%) 8/35 (23%) 13/33 (39%) |
|FIRST INCIDENCE (DAYS) | 731 (T) 485 476 | 731 (T) 731 (T) 589 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.179 P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.179 P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.179 P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P=0.277 P<0.001 ** |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) | 0/50 (0%) 3/50 (6%) 2/49 (4%) |
|ADJUSTED (b) | 3.3% 0.0% 8.3% | 0.0% 8.3% 6.1% |
|TERMINAL (d) | 1/30 (3%) 0/20 (0%) 1/21 (5%) | 0/41 (0%) 2/35 (6%) 2/33 (6%) |
|FIRST INCIDENCE (DAYS) | 731 (T) --- 670 | --- 710 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.277 P=0.581N P=0.385 | P=0.155 P=0.097 P=0.192 |
|INCIDENTAL TUMOR | P=0.341 P=0.581N P=0.479 | P=0.181 P=0.118 P=0.192 |
|LOGISTIC REGRESSION | P=0.318 P=0.581N P=0.444 | P=0.166 P=0.105 P=0.192 |
|COCHRAN-ARMITAGE | P=0.360 | P=0.196 |
|FISHER EXACT | P=0.500N P=0.500 | P=0.121 P=0.242 |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 14/50 (28%) 30/50 (60%) | 5/50 (10%) 11/50 (22%) 22/49 (45%) |
|ADJUSTED (b) | 6.7% 54.8% 80.4% | 12.2% 30.5% 54.2% |
|TERMINAL (d) | 2/30 (7%) 9/20 (45%) 14/21 (67%) | 5/41 (12%) 10/35 (29%) 15/33 (45%) |
|FIRST INCIDENCE (DAYS) | 731 (T) 485 476 | 731 (T) 710 589 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.042 * P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.047 * P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P=0.043 * P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P=0.086 P<0.001 ** |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/50 (0%) | 1/50 (2%) 1/50 (2%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 10.0% 0.0% | 2.4% 2.3% 0.0% |
|TERMINAL (d) | 0/30 (0%) 2/20 (10%) 0/21 (0%) | 1/41 (2%) 0/35 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- 731 (T) --- | 731 (T) 675 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.583 P=0.154 (e) | P=0.381N P=0.733 P=0.543N |
|INCIDENTAL TUMOR | P=0.583 P=0.154 (e) | P=0.308N P=0.751N P=0.543N |
|LOGISTIC REGRESSION | P=0.583 P=0.154 (e) | P=0.333N P=0.761N P=0.543N |
|COCHRAN-ARMITAGE | P=0.669 | P=0.335N |
|FISHER EXACT | P=0.247 (e) | P=0.753N P=0.505N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 4/50 (8%) 19/50 (38%) | 3/50 (6%) 4/50 (8%) 17/49 (35%) |
|ADJUSTED (b) | 26.7% 18.5% 68.4% | 7.3% 10.4% 48.2% |
|TERMINAL (d) | 8/30 (27%) 3/20 (15%) 13/21 (62%) | 3/41 (7%) 2/35 (6%) 15/33 (45%) |
|FIRST INCIDENCE (DAYS) | 731 (T) 691 366 | 731 (T) 616 653 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.413N P<0.001 ** | P<0.001 ** P=0.423 P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.375N P=0.002 ** | P<0.001 ** P=0.552 P<0.001 ** |
|LOGISTIC REGRESSION | P=0.002 ** P=0.349N P=0.004 ** | P<0.001 ** P=0.487 P<0.001 ** |
|COCHRAN-ARMITAGE | P=0.005 ** | P<0.001 ** |
|FISHER EXACT | P=0.178N P=0.012 * | P=0.500 P<0.001 ** |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 13/50 (26%) 12/50 (24%) | 3/50 (6%) 3/50 (6%) 2/49 (4%) |
|ADJUSTED (b) | 19.4% 45.9% 38.3% | 6.7% 8.6% 6.1% |
|TERMINAL (d) | 5/30 (17%) 6/20 (30%) 5/21 (24%) | 1/41 (2%) 3/35 (9%) 2/33 (6%) |
|FIRST INCIDENCE (DAYS) | 729 455 502 | 675 731 (T) 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.027 * P=0.012 * P=0.031 * | P=0.514N P=0.590 P=0.595N |
|INCIDENTAL TUMOR | P=0.110 P=0.037 * P=0.110 | P=0.437N P=0.653 P=0.478N |
|LOGISTIC REGRESSION | P=0.064 P=0.023 * P=0.078 | P=0.461N P=0.639 P=0.528N |
|COCHRAN-ARMITAGE | P=0.087 | P=0.421N |
|FISHER EXACT | P=0.062 P=0.096 | P=0.661N P=0.510N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 17/50 (34%) 26/50 (52%) | 6/50 (12%) 7/50 (14%) 17/49 (35%) |
|ADJUSTED (b) | 38.7% 59.3% 76.8% | 13.7% 18.5% 48.2% |
|TERMINAL (d) | 11/30 (37%) 9/20 (45%) 14/21 (67%) | 4/41 (10%) 5/35 (14%) 15/33 (45%) |
|FIRST INCIDENCE (DAYS) | 729 455 366 | 675 616 653 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.023 * P<0.001 ** | P=0.001 ** P=0.392 P=0.002 ** |
|INCIDENTAL TUMOR | P=0.001 ** P=0.066 P=0.002 ** | P=0.002 ** P=0.532 P=0.004 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.055 P=0.001 ** | P=0.002 ** P=0.472 P=0.003 ** |
|COCHRAN-ARMITAGE | P=0.003 ** | P=0.004 ** |
|FISHER EXACT | P=0.189 P=0.004 ** | P=0.500 P=0.007 ** |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 17/50 (34%) 26/50 (52%) | 6/50 (12%) 7/50 (14%) 17/49 (35%) |
|ADJUSTED (b) | 38.7% 59.3% 76.8% | 13.7% 18.5% 48.2% |
|TERMINAL (d) | 11/30 (37%) 9/20 (45%) 14/21 (67%) | 4/41 (10%) 5/35 (14%) 15/33 (45%) |
|FIRST INCIDENCE (DAYS) | 729 455 366 | 675 616 653 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.023 * P<0.001 ** | P=0.001 ** P=0.392 P=0.002 ** |
|INCIDENTAL TUMOR | P=0.001 ** P=0.066 P=0.002 ** | P=0.002 ** P=0.532 P=0.004 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.055 P=0.001 ** | P=0.002 ** P=0.472 P=0.003 ** |
|COCHRAN-ARMITAGE | P=0.003 ** | P=0.004 ** |
|FISHER EXACT | P=0.189 P=0.004 ** | P=0.500 P=0.007 ** |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/49 (6%) 6/50 (12%) 11/50 (22%) | 4/50 (8%) 4/50 (8%) 7/49 (14%) |
|ADJUSTED (b) | 10.3% 21.6% 40.1% | 9.8% 10.8% 17.9% |
|TERMINAL (d) | 3/29 (10%) 2/20 (10%) 6/21 (29%) | 4/41 (10%) 2/35 (6%) 4/33 (12%) |
|FIRST INCIDENCE (DAYS) | 731 (T) 600 366 | 731 (T) 710 580 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.005 ** P=0.125 P=0.006 ** | P=0.135 P=0.554 P=0.176 |
|INCIDENTAL TUMOR | P=0.015 * P=0.191 P=0.019 * | P=0.219 P=0.612 P=0.293 |
|LOGISTIC REGRESSION | P=0.011 * P=0.184 P=0.015 * | P=0.194 P=0.584 P=0.272 |
|COCHRAN-ARMITAGE | P=0.015 * | P=0.193 |
|FISHER EXACT | P=0.254 P=0.022 * | P=0.643N P=0.251 |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/49 (4%) 4/50 (8%) 10/50 (20%) | 2/50 (4%) 5/50 (10%) 7/49 (14%) |
|ADJUSTED (b) | 6.2% 18.3% 34.6% | 4.9% 13.2% 19.2% |
|TERMINAL (d) | 1/29 (3%) 3/20 (15%) 4/21 (19%) | 2/41 (5%) 4/35 (11%) 5/33 (15%) |
|FIRST INCIDENCE (DAYS) | 675 687 589 | 731 (T) 421 580 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.003 ** P=0.209 P=0.006 ** | P=0.034 * P=0.167 P=0.045 * |
|INCIDENTAL TUMOR | P=0.009 ** P=0.277 P=0.024 * | P=0.055 P=0.167 P=0.078 |
|LOGISTIC REGRESSION | P=0.005 ** P=0.253 P=0.011 * | P=0.061 P=0.243 P=0.076 |
|COCHRAN-ARMITAGE | P=0.008 ** | P=0.057 |
|FISHER EXACT | P=0.349 P=0.015 * | P=0.218 P=0.075 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/49 (10%) 10/50 (20%) 18/50 (36%) | 6/50 (12%) 8/50 (16%) 13/49 (27%) |
|ADJUSTED (b) | 16.3% 37.2% 58.2% | 14.6% 20.6% 33.8% |
|TERMINAL (d) | 4/29 (14%) 5/20 (25%) 9/21 (43%) | 6/41 (15%) 5/35 (14%) 9/33 (27%) |
|FIRST INCIDENCE (DAYS) | 675 600 366 | 731 (T) 421 580 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.043 * P<0.001 ** | P=0.019 * P=0.284 P=0.025 * |
|INCIDENTAL TUMOR | P=0.001 ** P=0.083 P=0.002 ** | P=0.043 * P=0.322 P=0.054 |
|LOGISTIC REGRESSION | P<0.001 ** P=0.073 P=0.001 ** | P=0.042 * P=0.387 P=0.057 |
|COCHRAN-ARMITAGE | P=0.001 ** | P=0.041 * |
|FISHER EXACT | P=0.140 P=0.002 ** | P=0.387 P=0.056 |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Mammary Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 2/50 (4%) 4/50 (8%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 4.9% 9.5% 0.0% |
|TERMINAL (d) | 0/30 (0%) 0/20 (0%) 0/21 (0%) | 2/41 (5%) 0/35 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 731 (T) 616 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.285N P=0.287 P=0.287N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.139N P=0.468 P=0.287N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.216N P=0.358 P=0.287N |
|COCHRAN-ARMITAGE | (e) | P=0.228N |
|FISHER EXACT | (e) (e) | P=0.339 P=0.253N |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 3/50 (6%) 4/50 (8%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 7.1% 9.5% 2.6% |
|TERMINAL (d) | 0/30 (0%) 0/20 (0%) 0/21 (0%) | 2/41 (5%) 0/35 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 716 616 674 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.332N P=0.431 P=0.383N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.135N P=0.653 P=0.263N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.146N P=0.521 P=0.318N |
|COCHRAN-ARMITAGE | (e) | P=0.259N |
|FISHER EXACT | (e) (e) | P=0.500 P=0.316N |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 3/50 (6%) 4/50 (8%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 7.1% 9.5% 0.0% |
|TERMINAL (d) | 0/30 (0%) 0/20 (0%) 0/21 (0%) | 2/41 (5%) 0/35 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 716 616 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.169N P=0.431 P=0.161N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.056N P=0.653 P=0.119N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.115N P=0.521 P=0.144N |
|COCHRAN-ARMITAGE | (e) | P=0.122N |
|FISHER EXACT | (e) (e) | P=0.500 P=0.125N |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 3/50 (6%) 4/50 (8%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 7.1% 9.5% 2.6% |
|TERMINAL (d) | 0/30 (0%) 0/20 (0%) 0/21 (0%) | 2/41 (5%) 0/35 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 716 616 674 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.332N P=0.431 P=0.383N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.135N P=0.653 P=0.263N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.146N P=0.521 P=0.318N |
|COCHRAN-ARMITAGE | (e) | P=0.259N |
|FISHER EXACT | (e) (e) | P=0.500 P=0.316N |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Ovary |
| Granulosa Cell Tumor Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 5/45 (11%) 5/47 (11%) |
|ADJUSTED (b) | | 0.0% 16.1% 15.6% |
|TERMINAL (d) | | 0/41 (0%) 5/31 (16%) 5/32 (16%) |
|FIRST INCIDENCE (DAYS) | | --- 731 (T) 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.017 * P=0.015 * P=0.016 * |
|INCIDENTAL TUMOR | | P=0.017 * P=0.015 * P=0.016 * |
|LOGISTIC REGRESSION | | P=0.017 * P=0.015 * P=0.016 * |
|COCHRAN-ARMITAGE | | P=0.031 * |
|FISHER EXACT | | P=0.021 * P=0.024 * |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 1/14 (7%) 0/42 (0%) | 13/49 (27%) 5/14 (36%) 4/43 (9%) |
|ADJUSTED (b) | 0.0% 100.0% 0.0% | 30.1% 67.5% 12.5% |
|TERMINAL (d) | 0/30 (0%) 1/1 (100%) 0/20 (0%) | 11/41 (27%) 4/6 (67%) 4/32 (13%) |
|FIRST INCIDENCE (DAYS) | --- 731 (T) --- | 690 690 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.623 P=0.004 ** (e) | P=0.058N P=0.194 P=0.055N |
|INCIDENTAL TUMOR | P=0.623 P=0.004 ** (e) | P=0.054N P=0.062 P=0.049N* |
|LOGISTIC REGRESSION | P=0.623 P=0.004 ** (e) | P=0.052N P=0.059 P=0.046N* |
|COCHRAN-ARMITAGE | P=0.684 | P=0.031N* |
|FISHER EXACT | P=0.226 (e) | P=0.360 P=0.030N* |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/48 (2%) 0/14 (0%) 0/42 (0%) | 1/49 (2%) 0/14 (0%) 2/43 (5%) |
|ADJUSTED (b) | 2.9% 0.0% 0.0% | 2.4% 0.0% 5.3% |
|TERMINAL (d) | 0/30 (0%) 0/1 (0%) 0/20 (0%) | 1/41 (2%) 0/6 (0%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 683 --- --- | 731 (T) --- 589 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.309N P=0.539N P=0.554N | P=0.317 P=0.868N P=0.435 |
|INCIDENTAL TUMOR | P=0.214N (e) P=0.393N | P=0.375 P=0.868N P=0.561 |
|LOGISTIC REGRESSION | P=0.328N P=0.932N P=0.529N | P=0.351 P=0.868N P=0.548 |
|COCHRAN-ARMITAGE | P=0.316N | P=0.337 |
|FISHER EXACT | P=0.774N P=0.533N | P=0.778N P=0.451 |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 0/50 (0%) 3/50 (6%) | 0/50 (0%) 0/50 (0%) 0/49 (0%) |
|ADJUSTED (b) | 13.3% 0.0% 10.4% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 4/30 (13%) 0/20 (0%) 1/21 (5%) | 0/41 (0%) 0/35 (0%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | 731 (T) --- 626 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.539N P=0.123N P=0.652N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.479N P=0.123N P=0.580N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.465N P=0.123N P=0.569N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.406N | (e) |
|FISHER EXACT | P=0.059N P=0.500N | (e) (e) |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibrosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 15/50 (30%) 15/50 (30%) 11/50 (22%) | 2/50 (4%) 2/50 (4%) 5/49 (10%) |
|ADJUSTED (b) | 39.4% 46.3% 36.3% | 4.6% 4.8% 13.8% |
|TERMINAL (d) | 8/30 (27%) 4/20 (20%) 5/21 (24%) | 1/41 (2%) 1/35 (3%) 3/33 (9%) |
|FIRST INCIDENCE (DAYS) | 464 432 485 | 690 347 672 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.498N P=0.271 P=0.520N | P=0.103 P=0.653 P=0.147 |
|INCIDENTAL TUMOR | P=0.103N P=0.519N P=0.173N | P=0.140 P=0.508N P=0.241 |
|LOGISTIC REGRESSION | P=0.118N P=0.450 P=0.273N | P=0.153 P=0.604N P=0.208 |
|COCHRAN-ARMITAGE | P=0.216N | P=0.140 |
|FISHER EXACT | P=0.586N P=0.247N | P=0.691N P=0.210 |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 3/50 (6%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 0.0% 7.7% 0.0% |
|TERMINAL (d) | 0/30 (0%) 0/20 (0%) 0/21 (0%) | 0/41 (0%) 1/35 (3%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | --- 688 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.587 P=0.103 (e) |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.579N P=0.139 (e) |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.632 P=0.118 (e) |
|COCHRAN-ARMITAGE | (e) | P=0.634 |
|FISHER EXACT | (e) (e) | P=0.121 (e) |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, Sarcoma, |
| Neurofibroma, or Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 17/50 (34%) 15/50 (30%) 12/50 (24%) | 2/50 (4%) 2/50 (4%) 5/49 (10%) |
|ADJUSTED (b) | 44.9% 46.3% 40.3% | 4.6% 4.8% 13.8% |
|TERMINAL (d) | 10/30 (33%) 4/20 (20%) 6/21 (29%) | 1/41 (2%) 1/35 (3%) 3/33 (9%) |
|FIRST INCIDENCE (DAYS) | 464 432 485 | 690 347 672 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.450N P=0.384 P=0.480N | P=0.103 P=0.653 P=0.147 |
|INCIDENTAL TUMOR | P=0.085N P=0.372N P=0.154N | P=0.140 P=0.508N P=0.241 |
|LOGISTIC REGRESSION | P=0.193N P=0.567N P=0.220N | P=0.153 P=0.604N P=0.208 |
|COCHRAN-ARMITAGE | P=0.161N | P=0.140 |
|FISHER EXACT | P=0.415N P=0.189N | P=0.691N P=0.210 |
|=================================================================================================================================|
| |
|Spleen |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/26 (0%) 2/50 (4%) | 0/50 (0%) 0/19 (0%) 1/48 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 9.5% | 0.0% 0.0% 3.0% |
|TERMINAL (d) | 0/30 (0%) 0/4 (0%) 2/21 (10%) | 0/41 (0%) 0/8 (0%) 1/33 (3%) |
|FIRST INCIDENCE (DAYS) | --- --- 731 (T) | --- --- 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.085 (e) P=0.163 | P=0.264 (e) P=0.457 |
|INCIDENTAL TUMOR | P=0.085 (e) P=0.163 | P=0.264 (e) P=0.457 |
|LOGISTIC REGRESSION | P=0.085 (e) P=0.163 | P=0.264 (e) P=0.457 |
|COCHRAN-ARMITAGE | P=0.115 | P=0.285 |
|FISHER EXACT | (e) P=0.247 | (e) P=0.490 |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 2/50 (4%) | 0/50 (0%) 0/50 (0%) 2/49 (4%) |
|ADJUSTED (b) | 0.0% 3.1% 8.3% | 0.0% 0.0% 5.8% |
|TERMINAL (d) | 0/30 (0%) 0/20 (0%) 1/21 (5%) | 0/41 (0%) 0/35 (0%) 1/33 (3%) |
|FIRST INCIDENCE (DAYS) | --- 634 670 | --- --- 729 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.109 P=0.466 P=0.172 | P=0.081 (e) P=0.200 |
|INCIDENTAL TUMOR | P=0.162 P=0.545 P=0.254 | P=0.107 (e) P=0.262 |
|LOGISTIC REGRESSION | P=0.135 P=0.492 P=0.211 | P=0.081 (e) P=0.201 |
|COCHRAN-ARMITAGE | P=0.142 | P=0.093 |
|FISHER EXACT | P=0.500 P=0.247 | (e) P=0.242 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/20 (5%) 2/49 (4%) | 4/48 (8%) 0/6 (0%) 3/48 (6%) |
|ADJUSTED (b) | 0.0% 0.0% 9.0% | 9.4% 0.0% 9.4% |
|TERMINAL (d) | 0/30 (0%) 0/0 1/20 (5%) | 3/40 (8%) 0/0 3/32 (9%) |
|FIRST INCIDENCE (DAYS) | --- 617 691 | 655 --- 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.114 P=0.462 P=0.171 | P=0.534N P=0.517N P=0.613N |
|INCIDENTAL TUMOR | P=0.195 P=0.545 P=0.248 | P=0.480N (e) P=0.558N |
|LOGISTIC REGRESSION | P=0.154 P=0.205 P=0.193 | P=0.467N P=0.792N P=0.537N |
|COCHRAN-ARMITAGE | P=0.164 | P=0.420N |
|FISHER EXACT | P=0.286 P=0.242 | P=0.615N P=0.500N |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 2/50 (4%) 1/50 (2%) 0/49 (0%) |
|ADJUSTED (b) | | 4.9% 2.9% 0.0% |
|TERMINAL (d) | | 2/41 (5%) 1/35 (3%) 0/33 (0%) |
|FIRST INCIDENCE (DAYS) | | 731 (T) 731 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.182N P=0.555N P=0.287N |
|INCIDENTAL TUMOR | | P=0.182N P=0.555N P=0.287N |
|LOGISTIC REGRESSION | | P=0.182N P=0.555N P=0.287N |
|COCHRAN-ARMITAGE | | P=0.145N |
|FISHER EXACT | | P=0.500N P=0.253N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 2/50 (4%) | 4/50 (8%) 5/50 (10%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 10.0% 9.5% | 9.3% 11.7% 3.0% |
|TERMINAL (d) | 0/30 (0%) 2/20 (10%) 2/21 (10%) | 3/41 (7%) 1/35 (3%) 1/33 (3%) |
|FIRST INCIDENCE (DAYS) | --- 731 (T) 731 (T) | 675 548 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.110 P=0.154 P=0.163 | P=0.235N P=0.430 P=0.254N |
|INCIDENTAL TUMOR | P=0.110 P=0.154 P=0.163 | P=0.111N P=0.612 P=0.206N |
|LOGISTIC REGRESSION | P=0.110 P=0.154 P=0.163 | P=0.153N P=0.537 P=0.202N |
|COCHRAN-ARMITAGE | P=0.176 | P=0.164N |
|FISHER EXACT | P=0.247 P=0.247 | P=0.500 P=0.187N |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 2/50 (4%) | 5/50 (10%) 6/50 (12%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 10.0% 9.5% | 11.7% 14.3% 3.0% |
|TERMINAL (d) | 0/30 (0%) 2/20 (10%) 2/21 (10%) | 4/41 (10%) 2/35 (6%) 1/33 (3%) |
|FIRST INCIDENCE (DAYS) | --- 731 (T) 731 (T) | 675 548 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.110 P=0.154 P=0.163 | P=0.166N P=0.417 P=0.163N |
|INCIDENTAL TUMOR | P=0.110 P=0.154 P=0.163 | P=0.076N P=0.581 P=0.129N |
|LOGISTIC REGRESSION | P=0.110 P=0.154 P=0.163 | P=0.098N P=0.524 P=0.124N |
|COCHRAN-ARMITAGE | P=0.176 | P=0.103N |
|FISHER EXACT | P=0.247 P=0.247 | P=0.500 P=0.107N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 6/50 (12%) 9/50 (18%) | 16/50 (32%) 11/50 (22%) 21/49 (43%) |
|ADJUSTED (b) | 20.4% 24.4% 28.8% | 35.4% 25.8% 48.4% |
|TERMINAL (d) | 2/30 (7%) 4/20 (20%) 3/21 (14%) | 12/41 (29%) 5/35 (14%) 11/33 (33%) |
|FIRST INCIDENCE (DAYS) | 432 501 257 | 655 592 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.284 P=0.590N P=0.343 | P=0.076 P=0.329N P=0.086 |
|INCIDENTAL TUMOR | P=0.539 P=0.350N P=0.558N | P=0.239 P=0.129N P=0.260 |
|LOGISTIC REGRESSION | P=0.440 P=0.431N P=0.505 | P=0.220 P=0.119N P=0.179 |
|COCHRAN-ARMITAGE | P=0.445 | P=0.150 |
|FISHER EXACT | P=0.387N P=0.500 | P=0.184N P=0.182 |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 6/50 (12%) 9/50 (18%) | 16/50 (32%) 11/50 (22%) 21/49 (43%) |
|ADJUSTED (b) | 20.4% 24.4% 28.8% | 35.4% 25.8% 48.4% |
|TERMINAL (d) | 2/30 (7%) 4/20 (20%) 3/21 (14%) | 12/41 (29%) 5/35 (14%) 11/33 (33%) |
|FIRST INCIDENCE (DAYS) | 432 501 257 | 655 592 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.284 P=0.590N P=0.343 | P=0.076 P=0.329N P=0.086 |
|INCIDENTAL TUMOR | P=0.539 P=0.350N P=0.558N | P=0.239 P=0.129N P=0.260 |
|LOGISTIC REGRESSION | P=0.440 P=0.431N P=0.505 | P=0.220 P=0.119N P=0.179 |
|COCHRAN-ARMITAGE | P=0.445 | P=0.150 |
|FISHER EXACT | P=0.387N P=0.500 | P=0.184N P=0.182 |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 22/50 (44%) 38/50 (76%) | 24/50 (48%) 24/50 (48%) 39/49 (80%) |
|ADJUSTED (b) | 49.8% 71.9% 92.5% | 54.4% 59.8% 88.5% |
|TERMINAL (d) | 14/30 (47%) 12/20 (60%) 18/21 (86%) | 21/41 (51%) 19/35 (54%) 28/33 (85%) |
|FIRST INCIDENCE (DAYS) | 683 485 366 | 655 616 528 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.010 * P<0.001 ** | P<0.001 ** P=0.306 P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.035 * P<0.001 ** | P<0.001 ** P=0.444 P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.035 * P<0.001 ** | P<0.001 ** P=0.434 P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P=0.001 ** |
|FISHER EXACT | P=0.151 P<0.001 ** | P=0.579N P=0.001 ** |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | VEHICLE 25 MG/KG 50 MG/KG | VEHICLE 25 MG/KG 50 MG/KG |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 28/50 (56%) 33/50 (66%) 35/50 (70%) | 24/50 (48%) 26/50 (52%) 33/49 (67%) |
|ADJUSTED (b) | 63.6% 86.8% 81.0% | 51.0% 54.6% 71.7% |
|TERMINAL (d) | 14/30 (47%) 15/20 (75%) 13/21 (62%) | 18/41 (44%) 14/35 (40%) 20/33 (61%) |
|FIRST INCIDENCE (DAYS) | 432 432 257 | 655 347 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.017 * P=0.025 * P=0.026 * | P=0.014 * P=0.239 P=0.014 * |
|INCIDENTAL TUMOR | P=0.226 P=0.139 P=0.313 | P=0.070 P=0.551N P=0.063 |
|LOGISTIC REGRESSION | P=0.201 P=0.092 P=0.295 | P=0.044 * P=0.511 P=0.056 |
|COCHRAN-ARMITAGE | P=0.088 | P=0.033 * |
|FISHER EXACT | P=0.206 P=0.107 | P=0.421 P=0.040 * |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 35/50 (70%) 39/50 (78%) 47/50 (94%) | 33/50 (66%) 41/50 (82%) 47/49 (96%) |
|ADJUSTED (b) | 79.5% 97.5% 97.9% | 70.2% 82.0% 97.9% |
|TERMINAL (d) | 21/30 (70%) 19/20 (95%) 20/21 (95%) | 27/41 (66%) 26/35 (74%) 32/33 (97%) |
|FIRST INCIDENCE (DAYS) | 432 432 257 | 655 347 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.013 * P=0.001 ** | P<0.001 ** P=0.023 * P<0.001 ** |
|INCIDENTAL TUMOR | P=0.002 ** P=0.064 P=0.009 ** | P<0.001 ** P=0.086 P<0.001 ** |
|LOGISTIC REGRESSION | P=0.002 ** P=0.040 * P=0.007 ** | P<0.001 ** P=0.058 P<0.001 ** |
|COCHRAN-ARMITAGE | P=0.002 ** | P<0.001 ** |
|FISHER EXACT | P=0.247 P=0.002 ** | P=0.055 P<0.001 ** |
|=================================================================================================================================|
DATE: 09/04/94 EXPERIMENT: 05024 TEST: 02 PAGE 18
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- N-METHYLOLACRYLAMIDE
TERMINAL SACRIFICE AT 105 WEEKS
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 123579-123579/123579
--multipart-boundary--